1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals

 
• By Alaric DeArment

The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent. 

Galderma announced results from the Phase III OLYMPIA 2 trial of nemolizumab in prurigo nodularis • Source: Shutterstock

The Swiss dermatology company Galderma S.A. is looking to edge into a niche market for the rare disease prurigo nodularis with nemolizumab, but the company could have to face big pharma rivals in the space. Regeneron Pharmaceuticals, Inc. and Sanofi are roughly three months out from securing another potential indication for their blockbuster autoimmune disease drug Dupixent (dupilumab) for the treatment of prurigo nodularis from the US Food and Drug Administration.

Dupixent is a blockbuster drug marketed by two large pharmaceutical companies, while Galderma is an experienced dermatology player but with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.